Clinical characteristics
| . | Patients . | Immunophenotype . | ALK-1 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | T . | B . | Null . | Not available . | Positive . | Negative . | Not available . | |
| No. | 89 | 100 | 40 | 5 | 31 | 13 | 35 | 8 | 46 |
| Sex | |||||||||
| Male | 62 | 69.6 | 31 | 2 | 20 | 9 | 24 | 5 | 33 |
| Female | 27 | 30.3 | 9 | 3 | 11 | 4 | 11 | 3 | 13 |
| Stage | |||||||||
| I | 8 | 8.9 | 1 | 0 | 4 | 3 | 3 | 2 | 3 |
| II | 20 | 22.5 | 12 | 0 | 6 | 2 | 8 | 3 | 9 |
| III | 55 | 61.8 | 22 | 5 | 20 | 8 | 21 | 3 | 31 |
| IV | 6 | 6.7 | 5 | 0 | 1 | 0 | 3 | 0 | 3 |
| Immunology | |||||||||
| T | 40 | 44.9 | 40 | 15 | 5 | 20 | |||
| B | 5 | 5.6 | 5 | 0 | 0 | 5 | |||
| Null | 31 | 34.8 | 31 | 16 | 2 | 13 | |||
| Not available | 13 | 14.6 | 13 | 4 | 1 | 8 | |||
| Tumor sites | |||||||||
| Lymph nodes | 80 | 89.8 | 36 | 5 | 28 | 11 | 32 | 8 | 40 |
| Mediastinal mass | 28 | 31.5 | 10* | 4 | 13* | 3* | 9 | 2 | 17 |
| Skin | 16 | 17.9 | 9† | 0 | 4† | 3† | 4 | 1 | 11 |
| Bone | 14 | 15.7 | 7 | 0 | 6 | 1 | 6 | 1 | 7 |
| Lung | 13 | 14.6 | 7 | 1 | 3 | 2 | 5 | 0 | 8 |
| Splenomegaly | 10 | 11.2 | 5 | 0 | 3 | 2 | 3 | 1 | 6 |
| Hepatomegaly | 22 | 24.7 | 11 | 1 | 9 | 1 | 7 | 2 | 13 |
| Soft tissue | 13 | 14.6 | 5 | 0 | 4 | 4 | 7 | 0 | 6 |
| Bone marrow | 5 | 5.6 | 4 | 0 | 1 | 0 | 3 | 0 | 2 |
| Central nervous system | 1 | 1.1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Effusions | 13 | 14.6 | 6 | 0 | 7 | 0 | 4 | 1 | 8 |
| B symptoms | 46 | 51.7 | 21 | 3 | 16 | 1 | 20 | 3 | 23 |
| Lactate dehydrogenase | |||||||||
| < 500 U/L | 77 | 86.5 | 35 | 5 | 26 | 11 | 32 | 8 | 37 |
| ≥ 500 U/L | 8 | 8.9 | 3 | 0 | 4 | 1 | 3 | 0 | 5 |
| Not available | 4 | 4.5 | 2 | 0 | 1 | 1 | 0 | 0 | 4 |
| . | Patients . | Immunophenotype . | ALK-1 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. . | % . | T . | B . | Null . | Not available . | Positive . | Negative . | Not available . | |
| No. | 89 | 100 | 40 | 5 | 31 | 13 | 35 | 8 | 46 |
| Sex | |||||||||
| Male | 62 | 69.6 | 31 | 2 | 20 | 9 | 24 | 5 | 33 |
| Female | 27 | 30.3 | 9 | 3 | 11 | 4 | 11 | 3 | 13 |
| Stage | |||||||||
| I | 8 | 8.9 | 1 | 0 | 4 | 3 | 3 | 2 | 3 |
| II | 20 | 22.5 | 12 | 0 | 6 | 2 | 8 | 3 | 9 |
| III | 55 | 61.8 | 22 | 5 | 20 | 8 | 21 | 3 | 31 |
| IV | 6 | 6.7 | 5 | 0 | 1 | 0 | 3 | 0 | 3 |
| Immunology | |||||||||
| T | 40 | 44.9 | 40 | 15 | 5 | 20 | |||
| B | 5 | 5.6 | 5 | 0 | 0 | 5 | |||
| Null | 31 | 34.8 | 31 | 16 | 2 | 13 | |||
| Not available | 13 | 14.6 | 13 | 4 | 1 | 8 | |||
| Tumor sites | |||||||||
| Lymph nodes | 80 | 89.8 | 36 | 5 | 28 | 11 | 32 | 8 | 40 |
| Mediastinal mass | 28 | 31.5 | 10* | 4 | 13* | 3* | 9 | 2 | 17 |
| Skin | 16 | 17.9 | 9† | 0 | 4† | 3† | 4 | 1 | 11 |
| Bone | 14 | 15.7 | 7 | 0 | 6 | 1 | 6 | 1 | 7 |
| Lung | 13 | 14.6 | 7 | 1 | 3 | 2 | 5 | 0 | 8 |
| Splenomegaly | 10 | 11.2 | 5 | 0 | 3 | 2 | 3 | 1 | 6 |
| Hepatomegaly | 22 | 24.7 | 11 | 1 | 9 | 1 | 7 | 2 | 13 |
| Soft tissue | 13 | 14.6 | 5 | 0 | 4 | 4 | 7 | 0 | 6 |
| Bone marrow | 5 | 5.6 | 4 | 0 | 1 | 0 | 3 | 0 | 2 |
| Central nervous system | 1 | 1.1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Effusions | 13 | 14.6 | 6 | 0 | 7 | 0 | 4 | 1 | 8 |
| B symptoms | 46 | 51.7 | 21 | 3 | 16 | 1 | 20 | 3 | 23 |
| Lactate dehydrogenase | |||||||||
| < 500 U/L | 77 | 86.5 | 35 | 5 | 26 | 11 | 32 | 8 | 37 |
| ≥ 500 U/L | 8 | 8.9 | 3 | 0 | 4 | 1 | 3 | 0 | 5 |
| Not available | 4 | 4.5 | 2 | 0 | 1 | 1 | 0 | 0 | 4 |